CCTG

BL.13

NCT03768570

BL13

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Status:

Recruiting

26459-200.png

II

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PD-1, PD-L1

Investigational

Product

Durvalumab

IgG1κ monoclonal antibody (i.v.)

Treatment Arms

o No Intervention: Surveillance

o Active Comparator: Durvalumab